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ABSTRACT
Photoreactive psoralens can form interstrand cross-
links (ICLs) in double-stranded DNA. In eubacteria,
the endonuclease UvrABC plays a key role in pro-
cessing psoralen ICLs. Psoralen-modified triplex-
forming oligonucleotides (TFOs) can be used to
direct ICLs to specific genomic sites. Previous stud-
ies of pyrimidine-rich methoxypsoralen–modified
TFOs indicated that the TFO inhibits cleavage by
UvrABC. Because different chemistries may alter
the processing of TFO-directed ICLs, we investi-
gated the effect of another type of triplex formed
by purine-rich TFOs on the processing of 4’-(hydro-
xymethyl)-4,5’,8-trimethylpsoralen (HMT) ICLs by
the UvrABC nuclease. Using an HMT-modified TFO
to direct ICLs to a specific site, we found that
UvrABC made incisions on the purine-rich strand
of the duplex ~3 bases from the 3’-side and ~9
bases from the 5’-side of the ICL, within the TFO-
binding region. In contrast to previous reports, the
UvrABC nuclease cleaved the TFO-directed psora-
len ICL with a greater efficiency than that of the
psoralen ICL alone. Furthermore, the TFO was dis-
sociated from its duplex binding site by UvrA and
UvrB. As mutagenesis by TFO-directed ICLs
requires nucleotide excision repair, the efficient pro-
cessing of these lesions supports the use of triplex
technology to direct DNA damage for genome
modification.
INTRODUCTION
Psoralens are photoreactive compounds that have been
used extensively in the treatment of skin disorders, such
as psoriasis (1). These planar, heterocyclic molecules can
intercalate into double-stranded DNA, and with absorp-
tion of photons at 365nm, can form adducts with pyrimi-
dine bases. Psoralen molecules contain two photoreactive
double bonds, a 3–4 double bond on the pyrone side and a
40–50 bond on the furan side that can form DNA inter-
strand crosslinks (ICLs) preferentially at 50-TpA-30 sites in
double-stranded DNA (2–4).
In bacteria, the three-component endonuclease,
UvrABC, plays an important role in the processing and
removal of ICLs. UvrABC has been shown to hydrolyze
the 9th phosphodiester bond to the 50-side and the 3rd
phosphodiester bond to the 30-side of a psoralen ICL
(5,6). In this process, dimerized UvrA binds UvrB in a
search for damage-induced conformational changes in
the double helix. After DNA damage and/or helical dis-
tortions are identiﬁed, UvrA is released from the DNA
and UvrC is recruited to the UvrB-DNA preincision com-
plex. UvrC then cleaves on the 30-side of the damaged site,
followed by a second cleavage on the 50-side [reviewed in
(7,8)].
Triplex-forming oligonucleotides (TFOs) are single-
stranded oligonucleotides that can bind speciﬁc purine-
rich stretches of DNA via Hoogsteen hydrogen bonding
through the major groove of the duplex DNA, thereby
forming a triplex DNA structure (9,10). Psoralen-modiﬁed
TFOs can be used to create ICLs at unique sites after
irradiation with UVA light making this a useful tool for
directing site-speciﬁc DNA damage both in vitro and
in vivo [reviewed in (11)]. It has been shown that 40-(hydro-
xymethyl)-4,50,8-trimethylpsoralen (HMT) forms primar-
ily 40–50-furan-sided monoadducts on the purine-rich
strand of the target duplex substrate when targeted with
a purine-rich TFO. These monoadducts are readily con-
verted to ICLs with thymidine on the complementary
pyrimidine-rich strand (12). In contrast, monoadducts
generated on thymidine in the pyrimidine strand are
mainly 3,4-pyrone-sided monoadducts which undergo
minimal conversion to ICLs (12). In the absence of triplex
formation (i.e. with an HMT ICL only) UvrABC prefer-
entially incises the furan-side-adducted strand of an HMT
ICL at a 50-TpA-30 site (6).
Previous studies of pyrimidine-rich methoxypsoralen
(MOP)-modiﬁed TFOs have indicated that the presence
of the third strand inhibits cleavage by the UvrABC
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(13), presumably due to the third strand blocking the
nuclease incision site in the underlying duplex substrate.
However, since diﬀerent binding and crosslinking chemis-
tries may alter the processing of TFO-directed ICLs, here
we investigated the eﬀect of purine-rich TFOs on the pro-
cessing of HMT ICLs by puriﬁed UvrA, UvrB and UvrC
subunits. Whereas pyrimidine-rich TFOs used previously
bind to the purine-rich strand of the target duplex in the
same 50–30 orientation as the purine-rich strand and
require acidic conditions for binding, purine-rich TFOs
bind in the major groove at physiological pH in an anti-
parallel orientation such that the third strand TFO has the
opposite 50–30 orientation as the purine-rich duplex strand.
Our studies demonstrate eﬃcient cleavage within the
TFO binding site of the TFO-directed psoralen ICL by
UvrABC compared to the ICL alone, in contrast to pub-
lished work utilizing a pyrimidine-rich MOP-modiﬁed
TFO (13). Furthermore, we show that binding of UvrA
and UvrB to the TFO-directed ICL results in dissociation
of the TFO from its duplex binding site. Our results sug-
gest that the TFO does not hinder cleavage by the
UvrABC complex, and therefore supports the use of tri-
plex technology as a powerful means to induce site-speciﬁc
DNA damage to facilitate genome modiﬁcation.
MATERIALS AND METHODS
Oligonucleotides
The psoralen-modiﬁed oligonucleotide (psoAG30) and
psoralen-modiﬁed disulﬁde linked oligonucleotide (pso-
SS-AG30) were synthesized and HPLC puriﬁed by
Midland Certiﬁed Reagent Co. (Midland, TX, USA). The
50-psoralen-modiﬁed oligonucleotides were synthesized
with the derivative 2-[40-(hydroxymethyl)-4,50,8-tri-
methylpsoralen]-hexyl-1-O-(2-cyanoethyl)-(N,N-diisopro-
pyl)-phosphoramidite.Thedisulﬁde-linkedoligonucleotide
was designed with a disulﬁde bridge between the psoralen
moiety and the oligonucleotide. Primers for PCR prepara-
tions of duplex substrate were synthesized by Integrated
DNA Technologies (Coralville, IA, USA). Primers were
designed to amplify a 120-bp region of the pSupFG1
plasmid encompassing the supF TFO target site, which
has been shown to be bound by nucleotide excision
repair (NER) factors in the presence of a TFO-directed
HMT ICL (14).
Substratepreparation
Target duplex DNA was synthesized by PCR ampliﬁca-
tion of a 120-bp region of the pSupFG1 plasmid contain-
ing the supF TFO target site (14). To create target duplex
that was 50-radiolabeled on either the purine-rich strand or
the pyrimidine-rich strand, the appropriate PCR primer
was 50-end-labeled using [g-
32P]ATP and T4 polynucleo-
tide kinase prior to the PCR reaction. The 120-bp PCR
product was gel puriﬁed on a 15% native polyacrylamide
gel. The 50-end-labeled substrate was incubated 12–16h in
triplex binding buﬀer (10mM MgCl2, 10mM Tris, pH 7.6)
with a 50- to 100-fold excess of psoAG30 or pso-SS-
AG30. Samples were irradiated with 1.8J/cm
2 of 365nm
UVA light to crosslink the psoralen-modiﬁed TFO to the
duplex substrate. Substrates crosslinked to pso-SS-AG30
were incubated with 100mM DTT at 658C for 3h to
reduce the disulﬁde bond and remove the TFO.
Substrates containing the crosslink only (ICL) or the
crosslink with the TFO covalently attached (TFO-ICL)
were puriﬁed from denaturing 6% polyacrylamide gels,
electroeluted and puriﬁed over MicroSpin G-25 columns
(GE Healthcare, Buckinghamshire, UK). To reanneal
crosslinked substrates, samples were heated to 958C for
5min and allowed to cool to room temperature ( 5h)in
10mM Tris, pH 7.8, 20mM NaCl. Substrates were repuri-
ﬁed over MicroSpin G-25 columns and reincubated in
triplex-binding buﬀer for at least 2h.
The 30-end-labeled substrate was made by labeling
duplex DNA using deoxyadenosine 50-triphosphate,
30[a-
32P]-(cordycepin 50-triphosphate) (Perkin Elmer Life
Sciences, Boston, MA, USA) and terminal transferase.
The 30-end-labeled duplex substrate was either gel puriﬁed
directly on a native polyacrylamide gel or digested with
MluI to remove the 30-end label on the pyrimidine strand
prior to gel puriﬁcation. Both digested and undigested
substrates were incubated in triplex-binding buﬀer with
psoAG30 followed by irradiation with UVA as mentioned
above. Crosslinked substrate was isolated as described
earlier.
To create a substrate labeled on the 30-end of the
TFO, psoAG30 was labeled using deoxyadenosine
50-triphosphate, 30[a-
32P]-(cordycepin 50-triphosphate)
and terminal transferase. Labeled TFO was incubated in
triplex-binding buﬀer with duplex DNA followed by irra-
diation with UVA, as above. Crosslinked substrate was
isolated as described earlier.
The positive control (F2650) is a 50-bp duplex with a
ﬂuorescein-adducted thymine at base 26 in the duplex. It
has previously been shown to be an eﬃcient substrate of
UvrABC (15,16). F2650 was prepared by labeling the
50-end of the ﬂuorescein-adducted strand as described ear-
lier. The ﬂuorescein-adducted strand was then puriﬁed
over a MicroSpin G-25 column and annealed to its com-
plementary strand.
UvrABC protein
Wild-type Bacillus caldotenax UvrA, B. caldotenax UvrB
and Thermatoga maritima UvrC subunits were prepared
as previously described (17). Proteins were stored at
 208C.
DNasefootprinting
Substrates were incubated for 5min at 228C with 0.001U
DNase I (Roche Applied Science, Indianapolis, IN, USA)
in triplex-binding buﬀer in a total volume of 10ml. The
reactions were stopped by addition of EDTA (80mM ﬁnal
concentration) and Herring sperm DNA (40mg). Samples
were heated to 958C in formamide loading buﬀer, sub-
jected to polyacrylamide gel electrophoresis (PAGE)
on a denaturing 12% gel, and analyzed using the Storm
820 Phosphorimager (Molecular Dynamics, Sunnyvale,
CA, USA).
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Target duplex DNA was 50-end-labeled with [g-
32P]ATP
and incubated with increasing concentrations of TFO
(psoAG30) at 378C for 12–16h in triplex-binding buﬀer
(10mM MgCl2, 10mM Tris, pH 7.6). Samples were either
run directly on a 12% TBM (89mM Tris, 89mM Boric
acid and 10mM MgCl2) native polyacrylamide gel at 70V
or were incubated in UvrABC buﬀer (50mM Tris, pH 7.5,
50mM KCl, 10mM MgCl2, 5mM DTT, 1mM ATP) at
558C for 30min prior to gel loading. Samples were pro-
tected from light during the procedure to prevent crosslink
formation and were visualized by autoradiography.
UvrABC incision assay
UvrA, UvrB and UvrC proteins were preheated at 658C
for 10min in UvrABC buﬀer. Substrate DNA was then
incubated with varying concentrations of UvrA as indi-
cated and 100nM UvrB in UvrABC buﬀer for 15min at
room temperature. UvrC was added to a ﬁnal concentra-
tion of 50nM, and the reaction mix was incubated at 558C
for 30min. Reactions were stopped by addition of EDTA
to a ﬁnal concentration of 20nM. Samples were heated to
958C in formamide loading buﬀer, subjected to PAGE on
a denaturing 6% gel and analyzed using the Storm 820
Phosphorimager.
UvrAand UvrB protein bindingassay
Target duplex was 50-end-labeled on the pyrimidine-rich
strand. Duplex, ICL and TFO-ICL substrates were pre-
pared as described earlier. Substrate DNA was incubated
alone, with 20nM UvrA, or with 20nM UvrA and 100
nM UvrB in UvrABC buﬀer at room temperature for
15min followed by incubation for 30min at 558C.
Loading dye was added to each sample to a ﬁnal concen-
tration of 8% glycerol, and samples were run on a native
4% polyacrylamide gel (89mM Tris, 89mM Boric acid,
2mM EDTA, 1mM ATP, 10mM MgCl2) at 100V (5V/
cm) at room temperature. Alternatively, in order to char-
acterize a quickly migrating band in the TFO-
ICL+UvrA+UvrB lane, samples were heated to 958C
for 5min following incubation with UvrA or
UvrA+UvrB and allowed to cool at room temperature
for 5min prior to the addition of loading buﬀer. Assays
were analyzed using the Storm 820 Phosphorimager.
RESULTS
Experimental design
The 120-bp duplex target was designed to contain a 30-bp
TFO binding site and a psoralen 50-AT-30 crosslinking site
(Figure 1). TFO-ICL substrate was created by incubating
the 120-bp duplex with the psoralen-modiﬁed TFO
(psoAG30) followed by irradiation with UVA at 1.8J/
cm
2 to crosslink the psoralen to the target duplex. ICL-
only substrate was constructed using a psoralen-disulﬁde-
linked TFO (pso-SS-AG30). Following incubation with
pso-SS-AG30 and UVA irradiation, the sample was trea-
ted with DTT to reduce the disulﬁde bond to release the
TFO. Crosslinked samples were then puriﬁed by denatur-
ing PAGE. The ﬂuorescein-adducted duplex F2650, which
has previously been shown to be eﬃciently incised by
UvrABC nuclease (15,16), was used as a positive control.
Thetriplexstructureispresentfollowingsubstratepurification
In order to conﬁrm the presence of the triplex structure
following gel puriﬁcation and reannealing of TFO-ICL
substrate, DNase footprinting was performed on duplex,
ICL only, TFO-ICL and unpuriﬁed TFO-ICL substrates
(Figure 2A). Digestion of the TFO-ICL substrate was
inhibited from approximately 60–90 bases (Figure 2A,
lane 6), as expected based on the presence of the bound
5′ aTCCTTCCCCCCCCACCACCCCCTCCCCCTC 3′
3′ tAGGAAGGGGGGGGTGGTGGGGGAGGGGGAG 5′
5′ pso-AGGAAGGGGGGGGTGGTGGGGGAGGGGGAG 3′
Psoralen-modified TFO ( psoAG30)
MluI
restrictionsite
TFO target site
5′
3′
3′ py
5′ pu
B
A
Figure 1. The target duplex and psoralen-modiﬁed TFO. (A) Space-ﬁlling model of a psoralen-modiﬁed TFO bound to its target duplex. The
psoralen moiety is shown in yellow and the TFO is shown in red bound to the purine-rich strand of the target duplex (blue) in the major groove. The
pyrimidine-rich strand is shown in green (21). (B) Psoralen-modiﬁed TFO and TFO binding site. The TFO binding site is shown in red, the psoralen
crosslinking site is shown in yellow and the pyrimidine-rich (py) and purine-rich (pu) strands are depicted in green and blue, respectively. The
sequence of the TFO binding site is shown in bold capital letters, the psoralen crosslinking site is underlined and psoAG30, the psoralen-conjugated
TFO, is depicted in an antiparallel orientation relative to the purine-rich strand of the target duplex. The MluI restriction site was used to remove the
30-radiolabel on the pyrimidine strand. Figure 1A reprinted with permission from Vasquez et al., Biochemistry, 35, 10712–10719, Copyright 1996
American Chemical Society.
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observed with the unpuriﬁed TFO-ICL substrate
(Figure 2A, lane 4).
Triplex formationoccurs under theconditions of the
UvrABC incision assay
Since the thermophilic UvrABC nuclease functions at
558C, we wanted to assure that the triplex structure was
stable at this temperature. Target duplex DNA was end-
labeled and incubated with increasing concentrations of
TFO in triplex-binding buﬀer, or in UvrABC incision
assay buﬀer, as indicated (Figure 2B and C). Samples
were either run directly on a 12% TBM native gel or
were incubated in UvrABC buﬀer at 558C for 30min
prior to gel loading. Under both conditions the TFO
demonstrated a binding aﬃnity of  10
 8M for its target
duplex. To verify that the TFO was not simply reanneal-
ing to the duplex in the gel following incubation at 558C,
target duplex was mixed with increasing concentrations of
TFO in triplex-binding buﬀer and run immediately on the
gel without incubation. No binding was observed even at
high concentrations (data not shown), suggesting that the
TFO does not reanneal to its target duplex throughout
the course of the gel mobility shift assay. These results
suggest that the reaction conditions do not have a sub-
stantial eﬀect on TFO binding, a ﬁnding consistent with
published reports on the thermal stability of triplex DNA
structures (18–20).
UvrABC incises TFO-directed psoralen ICLs withahigher
efficiency but similar patternto that ofpsoralen ICLs alone
Substrate DNA was alternately labeled on the purine-rich
strand, pyrimidine-rich strand or the third strand TFO in
order to monitor processing by the UvrABC nuclease.
Substrate DNA was then incubated with 20nM UvrA
and 100nM UvrB in UvrABC buﬀer for 15min at room
temperature. UvrC was added to a ﬁnal concentration of
50nM, and the reaction mixture was incubated at 558C for
30min. Samples were then subjected to denaturing PAGE
to determine the amount and types of incision products
generated.
Results from experiments with the substrate 50-end-
labeled on the purine-rich strand are shown in
Figure 3A. UvrABC has been shown to incise the
purine-rich strand containing the furan adduct more eﬃ-
ciently than the pyrimidine strand (containing the pyrone
adduct) in similar studies (6,13). Following incubation
with the UvrABC nuclease, both TFO-ICL and ICL-
only substrates produced incision products migrating
slightly slower than 80 bases (Figure 3A, lanes 2 and 6).
This is consistent with cutting of the purine strand  9
bases on the 50-side of the ICL (Figure 3B), which
would yield an 83-base product, placing the incision site
within the TFO-binding region. No incision product was
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Figure 2. Triplex formation occurs under conditions of the UvrABC
incision assay. (A) DNase footprint to verify presence of the triplex
structure. Substrate labeled on the 50-end of the purine-rich strand
was incubated  /+ DNase I as indicated. Lanes 1 and 2 contain
duplex, lanes 3 and 4 contain unpuriﬁed TFO-ICL substrate, lanes 5
and 6 contain gel-puriﬁed TFO-ICL and lanes 7 and 8 contain gel-
puriﬁed ICL only. A bracket indicates the protected region. (B) and
(C) TFO-binding assay. Target duplex DNA was end-labeled with
[g-
32P]ATP and incubated with increasing concentrations of TFO as
indicated. Samples were either incubated in standard triplex binding
buﬀer at 378C and subjected to native PAGE on a 12% TBM gel
(B) or were incubated in UvrABC buﬀer at 558C for 30min prior to
loading (C). Triplex formation occurs under both conditions (binding
aﬃnity of  10
 8M), indicating that the reaction conditions did not
aﬀect TFO binding.
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The ﬂuorescein-adducted substrate F2650 was used as a
positive control in the incision assays though may not be
shown in all ﬁgures for clarity of presentation. A repre-
sentative assay is shown in Figure 3E. Incision eﬃciencies
observed were similar to those reported previously on
ICL-containing substrates in the absence of a third
strand TFO (15,16). Interestingly, analysis of the incision
activity of the UvrABC nuclease on the TFO-ICL and
ICL-only substrates indicated that 50 incision of the
TFO-ICL substrate is more eﬃcient than 50 incision of
the ICL-only substrate (Figure 3F; 44 12.8% and
21 5.2%, respectively, P<0.05 using Student’s t-test;
the values obtained for incision activity on the TFO-ICL
and ICL substrates were normalized to the incision activ-
ity on the F2650 substrate). This is in contrast to published
work utilizing a pyrimidine-rich MOP-modiﬁed TFO (13).
These data suggest that the purine-rich TFO does not
inhibit the 50-incision activity of the UvrABC nuclease
under the conditions of our assay.
To gain more information on the nature of the incision
sites, the target duplex was 30-end-labeled on the purine-
rich strand of the target duplex. After incubation with the
UvrABC nuclease, samples were subjected to denaturing
PAGE and an incision product migrating between 20 and
30 bases was observed in the TFO-ICL lane (Figure 3C,
lane 1). This product size corresponds with UvrABC inci-
sion on the purine-rich strand  3 phosphodiester bonds on
the 30-side of the ICL (Figure 3D), which would generate a
26-base product, consistent with previous studies (13).
To determine whether the UvrABC nuclease incises the
pyrimidine-rich strand of the crosslinked target duplexes,
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Figure 3. UvrABC incision assay with the radiolabel on the purine-rich strand of the target duplex. (A) UvrABC incision assay with 50-end-labeled
purine-rich duplex target strand. Substrate DNA was incubated with puriﬁed UvrA (20nM), UvrB (100nM) and UvrC (50nM) as described in the
Materials and Methods section and subjected to denaturing PAGE on a 6% gel. Lanes 1 and 2 contain puriﬁed psoralen crosslinked duplex substrate
treated to remove the TFO (labeled as ICL)  /+ UvrABC, lanes 3 and 4 contain nondamaged duplex DNA (labeled as Dup)  /+ UvrABC and
lanes 5 and 6 contain puriﬁed TFO-directed psoralen ICL substrate with the TFO covalently attached (labeled as TFO-ICL)  /+ UvrABC. The bar
( ) indicates lanes that have been removed for clarity of presentation. (B) Expected incision sites for the UvrABC nuclease on ICL and TFO-ICL
substrates. The expected incision product is shown in red, the TFO is depicted in blue and incision sites are marked by arrows. A green star indicates
the position of the radiolabel. The pyrimidine-rich and purine-rich strands of the target duplex are labeled py and pu, respectively. The incision
product migrating between 80 and 90 bases corresponds with cleavage on the purine-rich strand  9 phosphodiester bonds on the 50-side of the ICL,
within the triplex binding site. (C) UvrABC incision assay with the purine-rich strand of the target duplex 30-end-labeled. Lanes 1 and 2 contain
TFO-ICL +/  UvrABC. The incision product migrating between 20 and 30 bases corresponds with cleavage on the purine-rich strand  3
phosphodiester bonds on the 30-side of the ICL. (D) Expected UvrABC incision sites on the TFO-ICL substrate. The ﬁgure is marked as in (B).
(E) UvrABC incision assay with ﬂuorescein-adducted positive control (F2650) 50-end-labeled on the ﬂuorescein-adducted strand. Lanes 1 and 2
contain F2650  /+ UvrABC. (F) Histogram indicating the average incision (as a percent of the total substrate) observed for ICL and TFO-ICL
substrates by the UvrABC nuclease. Incision assays were repeated at least three times. Data presented are  SD, P<0.05 using Student’s t-test.
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subjected to the UvrABC incision assay. For both
TFO-ICL and ICL-only substrates 50-incision eﬃciency
on the pyrimidine-rich strand was <3% (Figure 4).
However, an incision product of  220 bases was observed
by denaturing PAGE in the sample containing the TFO-
ICL substrate and the UvrABC nuclease (Figure 4A, lane
2), likely due to purine-rich strand incision. Similarly,
incubation of the ICL-only substrate with UvrABC pro-
duced two products migrating between 140 and 150 bases
(Figure 4C, lane 4), again suggesting that these products
were the result of cutting on the purine-rich strand of the
target duplex only (Figure 4B and D). Labeling of the
30-ends likewise revealed an incision product of  220bp
(Figure 4E, lane 2), but no detectable product of  88
bases as might be expected with cutting on the 30 side of
the ICL on the pyrimidine-rich strand (Figure 4F). These
results point to ineﬃcient incision by UvrABC on the
pyrimidine-rich strand compared to the purine-rich
strand of the target duplex on both the TFO-ICL and
the ICL-only substrates.
Since the presence of the TFO did not appear to inhibit
the incision activity of the UvrABC nuclease on the
purine-rich strand of the crosslinked triplex substrate,
we 30-end-labeled the TFO to observe its processing by
UvrABC. A product was observed at  220 bases, the
same size as the product seen when the pyrimidine-rich
strand was labeled. However, no products of the size
expected from TFO cleavage (<22 bases) were identiﬁed
as UvrABC incision products (data not shown), indicating
that UvrABC does not incise the TFO itself prior to inci-
sion of the purine-rich strand of the target duplex. This
suggests that the intact TFO remains covalently linked
(via the ICL) to the substrate following processing by
the UvrABC nuclease and that the TFO may be displaced
from the duplex target site during processing.
UvrAand UvrB binding displaces the TFO fromthe
targetduplex
It is known that UvrA2B binds damaged DNA, with
UvrA loading UvrB onto the site. UvrA is then released,
leaving the UvrB-DNA preincision complex (7). In order
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Nucleic Acids Research, 2008, Vol. 36, No. 22 7141to investigate the eﬀects of the TFO on damage recogni-
tion and binding by UvrA and UvrB, a gel mobility shift
assay was performed with radiolabeled substrates contain-
ing an ICL or a TFO-ICL in the presence of puriﬁed UvrA
and UvrB proteins. We found that binding of UvrA to the
ICL and to the TFO-ICL substrates was similar (<7%),
and that incubation of the substrates with both UvrA and
UvrB resulted in  40% binding by UvrB (Figure 5A,
lanes 9 and 12), suggesting that the increased incision
eﬃciency of the TFO-ICL substrate was not due to an
increase in recognition of or binding by the UvrA2B
complex. This is consistent with results reported by
Duval-Valentin et al. (13), with a pyrimidine-rich TFO.
As expected, incubation of F2650 with both UvrA and
UvrB resulted in eﬃcient ( 55%) binding by UvrB
(Figure 5A, lane 3). Interestingly, an additional product
migrating faster than UvrB-bound TFO-ICL and slightly
slower than unbound TFO-ICL was observed on the gel in
the sample containing TFO-ICL in the presence of both
UvrA and UvrB (Figure 5A, lane 12, band labeled ‘altered
substrate’). We speculated that this product may be the
result of either binding by partially degraded protein
and/or displacement of the TFO by UvrA and/or UvrB.
To test this, substrates were subjected to either proteinase
K treatment or heat denaturation following incubation
with either UvrA or UvrA and UvrB. The product was
sensitive to heat denaturation (Figure 5B) but not to pro-
teinase K (data not shown), consistent with structural
modiﬁcations of the TFO-ICL (such as altered hydrogen
bonding of the TFO induced by UvrA and/or UvrB).
To substantiate that formation of the UvrB preincision
complex was displacing the TFO, a binding reaction was
performed with nonirradiated TFO+duplex samples, to
form a noncovalent triplex substrate. We found that the
TFO was displaced from its binding site on the duplex
DNA substrate slightly by UvrA, but dramatically in the
presence of UvrA and UvrB (Figure 5C). Taken together,
it is likely that the additional product observed is due to
displacement of the TFO from its target duplex binding
site during formation of the UvrB–DNA complex.
UvrA concentration affects the incision efficiencies
of TFO-ICL andICL substratesdifferently
It has been reported that the cleavage eﬃciencies of both
ICLs and TFO-ICLs depend on the concentration of
UvrA, with the presence of a pyrimidine-rich third
strand inhibiting cleavage at low UvrA concentrations
(<70nM) (13). To investigate the eﬀects of UvrA concen-
tration on the cleavage eﬃciencies of the purine-rich TFO-
ICL substrate compared to the ICL alone, UvrABC inci-
sion assays were performed with concentrations of UvrA
ranging from 0nM to 70nM on substrates labeled on the
50-end of the purine-rich strand (Figure 6A and B). As
observed previously (13), the incision eﬃciency of the
ICL only increased with UvrA concentration to reach a
plateau between  20nM and 40nM. At higher concentra-
tions, the level of incision began to decrease. The incision
eﬃciency of the TFO-ICL substrate was similar to the
incision eﬃciency of the ICL-only substrate at lower con-
centrations of UvrA (<20nM). However, with UvrA con-
centrations of 20nM and higher, the incision eﬃciency of
the TFO-ICL was substantially higher than the incision
eﬃciency of the ICL only (Figure 6C).
DISCUSSION
Psoralens are photoreactive compounds that can form
ICLs preferentially at 50-TA-30 sites in double-stranded
DNA. Psoralen-modiﬁed TFOs can be used to target
psoralen molecules to speciﬁc sites in double-stranded
DNA (21,22), providing a tool for targeting genes and
directing site-speciﬁc DNA damage. However, despite
the potential utility of psoralen-modiﬁed TFOs in the bio-
medical and biotechnological ﬁelds, much remains to be
learned about the processing of these lesions by DNA
repair proteins. Here, we investigated the eﬀect of a
purine-rich TFO on the processing of psoralen ICLs by
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Figure 5. UvrA or UvrA+UvrB protein binding assay. UvrA or
UvrA+UvrB protein binding assays with 50-end-labeled pyrimidine-
rich duplex target strand. (A) Substrate DNA was incubated with pur-
iﬁed UvrA (20nM) or UvrA (20nM) and UvrB (100nM) as described
in the Materials and Methods section and subjected to 4% native
PAGE gel. Lanes 1–3 contain F2650 positive control with no protein,
UvrA or UvrA+UvrB, respectively. Lanes 4–6 contain nondamaged
duplex DNA with no protein, UvrA or UvrA+UvrB, respectively.
Lanes 7–9 contain puriﬁed ICL only with no protein, UvrA or
UvrA+UvrB, respectively. Lanes 10–12 contain puriﬁed TFO-ICL
substrate with no protein, UvrA or UvrA+UvrB, respectively. UvrB
binding was similar with ICL and TFO-ICL substrates ( 40%, lanes 9
and 12). An ‘altered substrate’ was observed when the TFO-ICL sub-
strate was incubated with UvrA+UvrB (lane 12). Asterisks mark an
artifact occurring in lanes containing crosslinked substrate. (B) UvrA
or UvrA+UvrB protein-binding assay to test for possible structural
modiﬁcations of TFO-ICL resulting in an ‘altered substrate’ following
incubation with UvrA or UvrA+UvrB. Substrate in the presence or
absence of UvrA and/or UvrB was either loaded directly on the gel
following incubation at 558C or heated to 958C prior to loading. The
‘altered substrate’ disappeared with heat denaturation, consistent with
structural modiﬁcations of the TFO-ICL. (C) UvrA or UvrA+UvrB
protein-binding assay to test for displacement of noncrosslinked TFO.
Noncrosslinked triplex substrate (pso-TFO+duplex in the absence of
UVA irradiation) was incubated with UvrA or UvrA+UvrB as
described and subjected to native PAGE (4% gel). Triplex substrate
was denatured to duplex form after incubation with UvrA+UvrB,
indicating displacement of the TFO from its target duplex binding site.
7142 Nucleic Acids Research, 2008, Vol. 36, No. 22the UvrABC nuclease. We used substrates containing
either a psoralen ICL alone or a TFO-directed ICL in
the presence of the puriﬁed UvrABC protein complex to
compare processing of psoralen ICLs in the presence or
absence of the third strand TFO. Our results show nearly
identical incision patterns of the ICL with or without the
TFO, in concordance with a previous study of TFO-ICLs
by Duval-Valentin et al. (13). However, while this pre-
vious study demonstrated that a pyrimidine-rich TFO
inhibited incision by the UvrABC nuclease, we observed
eﬃcient incision of a purine-rich TFO-ICL compared to
the ICL alone, likely due to the displacement of the TFO
by the UvrB–DNA complex.
In our study, the UvrABC nuclease generated incision
products consistent with cleavage on the purine-rich
strand of the target duplex approximately nine phospho-
diester bonds 50, and three phosphodiester bonds 30 to the
ICL in the presence or absence of the TFO. Pyrimidine
strand cleavage by the UvrABC nuclease was nearly unde-
tectable (<3%) with either substrate. This is in agreement
with previous work showing that UvrABC cuts predomi-
nantly on the furan-adducted side of an HMT ICL (6),
and that furan-sided adducts are produced on the purine-
rich strand of the target duplex when HMT is coupled to a
purine-rich TFO (12). Of note, the incision made on the
50-side of the ICL is within the TFO binding site, suggest-
ing that the UvrABC nuclease would either have to incise
the TFO ﬁrst, or displace it prior to cleavage of the purine-
rich strand of the underlying target duplex. The incision
assays using a TFO-ICL substrate 30-end-labeled on the
TFO showed no evidence of incision of the TFO (data not
shown), suggesting that the TFO may be displaced from
the duplex during processing by the UvrABC nuclease.
The UvrABC complex has been shown to release short
oligonucleotides annealed to single-stranded DNA, and
the length and amount of oligonucleotide released
increased in the presence of bulky DNA adducts (23,24).
It is hypothesized that the release of the oligonucleotide is
due to strand destabilization activity of the UvrABC
nuclease. A similar destabilization of the TFO could
allow access to the target incision site on the purine-rich
strand of the duplex. Consistent with this, our gel mobility
shift assay revealed an additional product migrating faster
than UvrB-bound TFO-ICL and slightly slower than
unbound TFO-ICL in the TFO-ICL+UvrA+UvrB
lane (Figure 5A, lane 12, band labeled ‘altered substate’).
The product was sensitive to heat denaturation, suggesting
that it resulted from structural modiﬁcations of the TFO-
ICL (such as altered hydrogen bonding of the TFO).
Repetition of the gel mobility shift assay with noncros-
slinked TFO+duplex samples (i.e. the TFO was not
covalently linked to the substrate) indicated that the
TFO was displaced from the duplex DNA substrate by
the UvrA2B complex. Taken together, it is likely that
the additional product observed is due to displacement
of the TFO during the formation of the stable UvrB–
DNA complex. Crystal structure studies indicate that for-
mation of the UvrB–DNA complex is marked by insertion
of the b-hairpin motif of UvrB between the strands
of duplex DNA (25,26). Insertion of the b-hairpin into
the DNA may disrupt TFO binding, thereby displacing
the TFO and allowing access to the incision site on the
target duplex.
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Figure 6. UvrA concentration-dependent incision eﬃciency of ICL and TFO-ICL substrates. ICL only (A) and TFO-ICL (B) substrates were labeled
on the 50-end of the purine-rich strand. Substrates were incubated with increasing concentrations of UvrA (0–70nM as indicated for each lane), 100
nM UvrB and 50nM UvrC for 30min at 558C. (C) Trend lines for ICL and TFO-ICL incision eﬃciencies with increasing concentrations of UvrA.
Relative incision values were determined by calculating the amount of product as a percent of total sample and normalizing to the incision eﬃciency
of ICL-only substrate at 20nM UvrA.
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nuclease showed more eﬃcient incision activity on the
TFO-ICL than the ICL alone. The increase in incision
observed with the purine-rich TFO-ICL substrate over
that of the ICL alone could be due to better recognition
and binding of the UvrA2B protein complex to the purine-
rich TFO-ICL compared to the ICL only. Some studies
have indicated that the binding aﬃnity of UvrA2Bi s
higher for bulkier substrates, and UvrA2B binding corre-
lates with incision activity (27,28). However, we found
that binding to both TFO-ICL and ICL substrates by
UvrA and UvrB was similar, demonstrating that the
increased incision eﬃciency of the TFO-ICL substrate
was not likely due to an increase in recognition of or
binding by the UvrA2B complex. This is consistent with
results reported by Duval-Valentin et al. (13) with a pyr-
imidine-rich TFO and with other reports that binding of
UvrA2B complex does not always correlate with incision
eﬃciency (29,30). Since the increased incision eﬃciency
observed in the presence of the triplex does not appear
to be the result of increased binding by UvrA2B, it may
be that binding and incision by UvrC is facilitated by the
presence of the third strand.
The eﬃcient incision of TFO-directed ICLs observed
here contrasts with previous work indicating that the pres-
ence of a pyrimidine-rich TFO inhibits incision of a psora-
len ICL by UvrABC (13). A possible explanation for
the discrepancy observed in the two studies could be the
nature of the psoralens and TFOs used. While the authors
of the previous study used a MOP-modiﬁed pyrimidine-
rich TFO, we used an HMT-modiﬁed purine-rich TFO.
Purine-rich TFOs bind in the major groove of the target
duplex DNA at physiological pH in an antiparallel orien-
tation to the purine-rich duplex strand, while pyrimidine-
rich TFOs require acidic conditions for triplex formation
and bind in the same 50–30 orientation as the purine-rich
duplex strand (31). Additionally, Duval-Valentin et al.
(13) reported that the furan side of the psoralen derivative
formed adducts primarily with the pyrimidine-rich strand
of its target duplex. With the substrate used in this study,
the furan side of the psoralen derivative forms adducts
primarily on the purine-rich strand of its target duplex.
It has been reported that sequence context, psoralen orien-
tation and adduct stereochemistry can aﬀect UvrABC
incision patterns and eﬃciencies (29,30,32). Since our
results with a 30-end-labeled TFO suggest that the TFO
is being displaced rather than incised, it is possible that the
chemical and physical diﬀerences in the TFO-ICL struc-
tures under study may aﬀect the ability of UvrABC to
displace the TFO after damage recognition. Consistent
with this, we demonstrated that higher concentrations of
UvrA resulted in increased incision eﬃciencies of the
purine-rich TFO-ICLs compared to the ICLs alone, per-
haps due to increased displacement of the TFO.
Another explanation for the discrepancy in the incision
eﬃciencies between the studies could be the result of high
temperature eﬀects due to the use of thermophilic
UvrABC nuclease in this study. Assays in the current
study were performed at 558C, and the elevated tempera-
ture might have aﬀected TFO binding. However, previous
thermodynamic studies have shown that triplexes formed
with purine-rich TFOs are stable at elevated temperatures
( 658C), and TFO binding can even stabilize the target
duplex at high temperatures (18–20). Consistent with this,
the gel mobility shift assay suggested that the reaction
conditions do not aﬀect the binding aﬃnity of the
purine-rich TFO used in this study.
In conclusion, psoralens are currently used in medicine
and research for their ability to form ICLs. TFOs are one
way to target such ICLs to speciﬁc sites in the genome,
providing a means to study ICL repair in vivo. However, if
psoralen-modiﬁed TFOs are to be used for research and
medical purposes, it is important to understand how the
presence of the TFO will inﬂuence the processing of psora-
len ICLs in both bacterial and mammalian systems.
Previously, we have shown that TFO-directed ICL lesions
are bound by the human NER damage/distortion recogni-
tion proteins (XPA-RPA and XPC-RAD23B) with high
aﬃnity and speciﬁcity (14,33,34), and is it known that
NER is required for TFO-induced mutagenesis (35).
Similarly, NER is required for excision of polyamine
adducts in both Escherichia coli and human cell-free
extracts (36); and NER, in conjunction with proteolytic
degradation, has been implicated in the repair of DNA–
protein crosslinks in bacterial and mammalian systems
(37–39). In this study, we demonstrate that the purine-
rich TFO enhances incision of the ICL by the UvrABC
complex. Further, we show that the presence of the
purine-rich TFO does not alter the incision pattern of
the ICL and that the TFO is displaced in the presence of
UvrA and UvrB. Together, these results indicate that
TFO-directed psoralen ICLs are recognized and processed
by the NER mechanism in both bacterial and mammalian
systems, supporting the use of triplex technology as a
powerful tool to induced site-speciﬁc DNA damage to
facilitate genome modiﬁcation.
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